Abstract

Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we compare tumor-infiltrating lymphocytes between EGFR mutant (EGFR-MT) and wild type (EGFR-WT) tumors through single-cell transcriptomic analysis. We find that B cells, CXCL13-producing follicular helper CD4+ T (TFH)-like cells, and tissue-resident memory CD8+ T (TRM)-like cells decreased in EGFR-MT tumors. The NOTCH-RBPJ regulatory network, which is vital for persistence of TRM state, is perturbed, and the interactions between TFH and B cells through the CXCL13-CXCR5 axis disappear in EGFR-MT tumors. Notably, the proportion of TRM-like cells is predictive for anti-PD-1 response in NSCLC. Our findings suggest that the impairment of TFH-B-TRM cooperation in tertiary lymphoid structure formation, accompanied by the dysregulation of TRM homeostasis and the loss of TFH-B crosstalk, underlies unfavorable anti-PD-1 response in EGFR-MT lung tumors.

Highlights

  • Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to Programmed death receptor-1 (PD-1) inhibitor through unclear mechanisms

  • We find that B cells, CXCL13-producing follicular helper CD4+ T (TFH)-like cells, and tissue-resident memory CD8+ T (TRM)-like cells are depleted in EGFR mutant (EGFR-MT) compared to EGFR wild-type (EGFR-WT)

  • To compare the cellular landscape between two different molecular subtypes of lung cancer based on the EGFR mutation status, we prepared tumor specimens surgically resected from 10 patients with NSCLC in stages IA–IIIA: five EGFR-WT and five EGFR-MT (Supplementary Data 1)

Read more

Summary

Introduction

Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Programmed death receptor-1 (PD-1) inhibitors improve survival outcomes by offering a durable response in patients with non-small cell lung cancer (NSCLC)[4,5,6,7]. These inhibitors are used as first- and second-line therapies for NSCLC4–7. A systematic comparison of single-cell transcriptome profiles between EGFR-WT and EGFR-MT tumors can reveal immune cell subsets that differentially accumulate between groups of molecular subtypes in NSCLC tumors, some of which may provide important clues regarding their difference in clinical outcomes. Multiple scRNA-seq studies have depicted immune cell landscapes of lung cancers[13,14,15,16], EGFR-WT and EGFR-MT tumors have not been systematically compared

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call